CLAIMS

1. Use of apitegromab in the manufacture of a medicament for the treatment of fatigue, impaired bulbar function, and/or impaired emptying in a subject having spinal muscular atrophy (SMA) and who receives an SMN therapy, wherein the subject suffers from fatigue, impaired bulbar function, and/or impaired emptying as measured by outcomes reported by the subject or a caregiver of the subject.

2. The use according to claim 1, wherein the subject's level of fatigue is assessed using a Patient-Reported Outcomes Measurement Information System (PROMIS).

3. The use according to any one of the preceding claims, wherein the impaired bulbar function is difficulty coughing, swallowing and/or feeding.

4. The use according to any one of the preceding claims, wherein the subject has one or more symptoms of impaired bulbar function selected from respiratory infection; use of assistive device; inability to cough or clear lung secretions; breathing difficulties; feeding/swallowing difficulties; difficulties with speech; and snoring.

5. The use according to any one of the preceding claims, wherein the impaired bulbar function is assessed using a Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (AMLFRSR), a Sydney Swallow Questionnaire (SSQ), a MD Anderson Dysphagia Inventory (MDADI), an SWAL-QoL score, or a Pediatric Functional Oral Intake Scale (p-FOIS).

6. The use according to any one of the preceding claims, wherein the impaired emptying is urgency and frequency of urination and/or bowel movement.

7. The use according to any one of the preceding claims, wherein the subject is prone to a respiratory infection.

8. The use according to any one of the preceding claims, wherein the subject has type 2 SMA or type 3 SMA.

9. The use according to any one of the preceding claims, wherein the subject has 2 copies, 3 copies, 4 copies, or 5 copies of the smn2 gene.

10. The use according to any one of the preceding claims, wherein the subject has ambulatory SMA.

11. The use according to any one of claims 1-9, wherein the subject has non-ambulatory SMA.

12. The use according to any one of the preceding claims, wherein the subject is 2 years of age or older at the time of starting the treatment.

13. The use according to claim 12, wherein the subject is 2-13 years of age.

14. The use according to claim 12, wherein the subject is 2-21 years of age.

15. The use according to any one of the preceding claims, wherein the SMN therapy is an smn2 splice modifier or an smn1 gene therapy.